News - dabrafenib

Filter

Current filters:

dabrafenib

Popular Filters

Australia’s PBS lists new medicines and increases cost threshold to A$20 million

Australia’s PBS lists new medicines and increases cost threshold to A$20 million

30-10-2013

The Australian Federal Minister for Health, Peter Dutton, has announced that the cost of 50 new and amended…

Asia-PacificdabrafenibHealthcarePharmaceuticalPoliticsSutent

FDA approves two GSK melanoma drugs and bioMerieux companion diagnostic

30-05-2013

The US Food and Drug Administration yesterday (May 29) approved two new oral drugs from UK pharma giant…

BioMerieuxdabrafenibGlaxoSmithKlineMekinistNorth AmericaOncologyPharmaceuticalRegulationTafinlartrametinib

GlaxoSmithKline initiates Ph III study to test dabrafenib and trametinib combo for BRAF positive melanoma

04-02-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) has initiated COMBI-AD, a Phase III study evaluating the combination…

BiotechnologydabrafenibGlaxoSmithKlineJapan TobaccoOncologyPharmaceuticalResearchtrametinib

GlaxoSmithKline files for EU and US approval for dabrafenib and trametinib

07-08-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) last week submitted regulatory filings in the European Union…

dabrafenibEuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationtrametinib

MEK inhibitors: new weapon in the fight against melanoma

24-06-2012

Cancer cell signaling has long been an attractive target for oncology drug development. Increased activation…

dabrafenibGlaxoSmithKlineOncologyPharmaceuticalResearchRochetrametinibZelboraf

More news from ASCO meeting

05-06-2012

More positive late-stage clinical data continued to roll out at the Annual Meeting of the American Society…

AlimtaBayerdabrafenibEli LillyGlaxoSmithKlineOncologyPharmaceuticalregorafenibResearchtrametinib

Malignant melanoma drug market to grow more than seven-fold to $1.5 billion in 2020

05-10-2011

The market for malignant melanoma drugs is forecast to expand more than seven-fold over the next decade,…

dabrafenibGlobalMarkets & MarketingOncologyPharmaceuticaltrametinibYervoyZelboraf

Back to top